Skip to main content
News > News > Open Therapeutics Integrates Overleaf Manuscript Development Platform Into Therapoid™

Open Therapeutics Integrates Overleaf Manuscript Development Platform Into Therapoid™




N E W S   R E L E A S E


For Immediate Release:

09 January 2018


Open Therapeutics Integrates Overleaf Manuscript Development Platform Into Therapoid™

Therapoid is a free and open scientific collaboration platform that crowdsources freely available biotechnologies and funding


Minneapolis, MN – Open Therapeutics™ announces the planned integration of Overleaf™ into its novel scientific collaboration platform, Therapoid™.


Overleaf is a unique collaborative writing manuscript development platform that supports scientists during their authorship. Its services to researchers enable them to author new research results and publish faster. Overleaf is an online LaTeX and Rich Text collaborative writing and publishing tool that makes the whole process of writing, editing and publishing scientific documents much quicker and easier.


According to John Hammersley, CEO, Overleaf, “Overleaf is always looking to help make global collaboration and scientific authorship easier, and when Jason reached out we were happy to help ensure the Therapoid™ user community can use the Overleaf platform to collaborate upon their research papers. We’re looking forward to hearing from authors who use Overleaf for their manuscripts!”


Jason E. Barkeloo, Founder and Executive Chairman of Open Therapeutics, “Overleaf is an important tool for the scientific community. We are grateful to Overleaf for enabling our open science collaboration platform users to develop their manuscripts within the Overleaf platform.”


Open Therapeutics hosts intellectual properties (IP) from institutions around the world. This IP is freely provided to researchers, particularly the underserved, and enables them to further the research at no cost.  The Therapoid platform also freely hosts grants, free lab equipment, manuscript development, and preprint server within its collaborative scientific ecosystem.



About Open Therapeutics LLC

Open Therapeutics ( is a crowdsourcing life science firm that creates and attracts therapeutic biotechnologies and crowdsources them for the global scientific community. The global research community can freely access the biotechnologies and funding to further the development of the biotechnologies at Therapoid™ ( The Company is headquartered in Minneapolis, MN, with laboratory operations in Covington, Kentucky, Cincinnati, OH, Amman, Jordan, and Bangalore, India.


About Overleaf

Founded in 2012 and serving a community of over 2 million users, Overleaf is an academic authorship tool that allows seamless collaboration and effortless manuscript submission, all underpinned by cloud-technology. By providing an intuitive online collaborative writing and publishing platform, Overleaf is making the process of writing, editing and publishing scientific documents quicker and easier. Researchers and academics can now write, collaborate, and publish with a single click, directly from the Overleaf web-app. Publishers and Institutions are partnering with Overleaf to provide customized writing templates, simple reference tool linking, and one-click publishing submission links. Supported by Digital Science, Overleaf aims to make science and research faster, more open and more transparent by bringing the whole scientific writing process into one place in the cloud – from idea, to writing, to review, to publication.

@overleaf on Twitter.

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.